R.A. Hannon - Concepedia

Author

R.A. Hannon

Also Known As

R A Hannon, R Hannon, R. A. Hannon, R. Hannon, R.A Hannon, R.A. Hannon, ROSEMARY A. HANNON, Rosemary A Hannon, Rosemary A. Hannon, Rosemary Hannon

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

University of Sheffield Northern General Hospital AstraZeneca (United Kingdom)AstraZeneca (United States)Università Campus Bio-Medico

About

R.A. Hannon is an author at University of Sheffield specializing in medicine, bone metabolism, and osteoporosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	969
2	Health Sciences	12	12	924
3	Public Health	2	2	304
4	Allergy	1	1	11
5	Applied Physiology	1	1	14

R.A. Hannon

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 Richard Eastell, Judith E. Adams, Robert E. Coleman, Journal of Clinical Oncology	2008	402
Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) Richard Eastell, R.A. Hannon, Jack Cuzick, Journal of Bone and Mineral Research	2006	318
Effect of feeding on bone turnover markers and its impact on biological variability of measurements J. A. Clowes, R.A. Hannon, T.S Yap, Bone Animal PhysiologyNutritionBone Turnover MarkersBone HealthBody Composition	2002	291
Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability R.A. Hannon, Aubrey Blumsohn, K.E. Naylor, Journal of Bone and Mineral Research	1998	262
Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial Catherine Van Poznak, R.A. Hannon, John R. Mackey, Journal of Clinical Oncology	2010	223
Biochemical markers of bone turnover in girls during puberty Aubrey Blumsohn, R.A. Hannon, R M Wrate, Clinical Endocrinology	1994	211
Circulating Estradiol and Osteoprotegerin as Determinants of Bone Turnover and Bone Density in Postmenopausal Women Angela J. Rogers, Ghorbat Saleh, R.A. Hannon, The Journal of Clinical Endocrinology & Metabolism GynecologyOrthopaedic SurgeryOsteoporosisBody CompositionOsteoarthritis	2002	202
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer J. Lester, David Dodwell, O.P. Purohit, Clinical Cancer Research	2008	189
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption R.A. Hannon, Jackie A. Clowes, Alison C. Eagleton, Bone Bone DiseaseBone HealthBone ResorptionMedicineOsteoarthritis	2003	157
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial R.A. Hannon, Glen Clack, Martin Rimmer, Journal of Bone and Mineral Research PharmacotherapyOsteoporosisOrthopaedic SurgeryBone DiseaseOncology	2009	110

Page 1